Literature DB >> 19442853

Human single chain monoclonal antibody that recognizes matrix protein of heterologous influenza A virus subtypes.

Ornnuthchar Poungpair1, Wanpen Chaicumpa, Kasem Kulkeaw, Santi Maneewatch, Kanyarat Thueng-in, Potjanee Srimanote, Pongsri Tongtawe, Thaweesak Songserm, Porntippa Lekcharoensuk, Pramuan Tapchaisri.   

Abstract

Matrix protein (M1) is predominant and has pivotal role in the influenza A virus replication and assembly. It is therefore an attractive target for antiviral drugs, siRNA studies, and therapeutic antibodies. Nevertheless, therapeutic antibody that interferes with the M1 multiplex function has never been developed. In this study, human single monoclonal antibody fragments (HuScFvs) to M1 were generated. Full length recombinant M1 (rM1) was produced from cDNA prepared from genome of highly pathogenic avian influenza virus, A/H5N1. The rM1 was used as an antigen in phage bio-panning to select phage clones displaying HuScFv from a human antibody phage display library. Several phage clones displaying HuScFv bound to the rM1 and harboring the respective huscfv gene inserts were isolated. RFLP experiments revealed multiple DNA banding patterns which indicated epitope/affinity diversity of the HuScFv. The HuScFv were tested for their binding to native M1 of homologous and heterologous influenza A viruses using ELISA as well as incorporating immunostaining and immunofluorescence studies with infected MDCK cells. One such protein produced from a selected phage clone blocked binding of M1 to viral RNA. The HuScFv in their in vivo functional format, e.g. cell-penetrating molecules, should be developed and tested as a broad spectrum anti-A/influenza.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19442853     DOI: 10.1016/j.jviromet.2009.03.010

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  6 in total

1.  Generation of human single-chain variable fragment antibodies specific to dengue virus non-structural protein 1 that interfere with the virus infectious cycle.

Authors:  Ornnuthchar Poungpair; Kunan Bangphoomi; Prapaipit Chaowalit; Nunghathai Sawasdee; Nichapatr Saokaew; Kiattawee Choowongkomon; Wanpen Chaicumpa; Pa-thai Yenchitsomanus
Journal:  MAbs       Date:  2014-01-15       Impact factor: 5.857

Review 2.  Botulinum neurotoxins and botulism: a novel therapeutic approach.

Authors:  Jeeraphong Thanongsaksrikul; Wanpen Chaicumpa
Journal:  Toxins (Basel)       Date:  2011-05-13       Impact factor: 4.546

3.  Characterization of an intracellular humanized single-chain antibody to matrix protein (M1) of H5N1 virus.

Authors:  He Sun; Guangmou Wu; Jiyuan Zhang; Yu Wang; Yue Qiu; Hongyang Man; Guoli Zhang; Zehong Li; Yuhuan Yue; Yuan Tian
Journal:  PLoS One       Date:  2022-03-31       Impact factor: 3.240

Review 4.  Discovery of Antivirals Using Phage Display.

Authors:  Esen Sokullu; Marie-Soleil Gauthier; Benoit Coulombe
Journal:  Viruses       Date:  2021-06-10       Impact factor: 5.048

5.  Novel bifunctional single-chain variable antibody fragments to enhance virolysis by complement: generation and proof-of-concept.

Authors:  Georg Huber; Zoltán Bánki; Renate Kunert; Heribert Stoiber
Journal:  Biomed Res Int       Date:  2014-01-12       Impact factor: 3.411

Review 6.  Evolving gene targets and technology in influenza detection.

Authors:  Anthony P Malanoski; Baochuan Lin
Journal:  Mol Diagn Ther       Date:  2013-10       Impact factor: 4.074

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.